Director at Perspective Therapeutics (CATX) awarded 50,000 stock options for 2026

Rhea-AI Filing Summary

Perspective Therapeutics director receives 2026 stock option grant. Director Lori A. Woods was granted a stock option to buy 50,000 shares at an exercise price of $0.0000 per share as her annual equity award for 2026. The option vests in full on March 2, 2027, assuming she continues to serve through the vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Woods Lori A

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.35	03/02/2026(1)		A		50,000		(2)	03/02/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

2. Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

	/s/ Lori A Woods by Chris Nenno, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Perspective Therapeutics (CATX) report for Lori A. Woods?

Perspective Therapeutics reported that director Lori A. Woods received a grant of stock options for 50,000 shares. The options were granted as her annual equity award for 2026 and carry a stated exercise price of $0.0000 per share.

When do Lori A. Woods’ new CATX stock options vest?

The 50,000 Perspective Therapeutics stock options granted to Lori A. Woods vest in full on March 2, 2027. Vesting is contingent on her continued service with the company through that vesting date, according to the disclosed terms.

What is the size of the stock option grant to Lori A. Woods at Perspective Therapeutics?

Lori A. Woods received a stock option grant covering 50,000 shares of Perspective Therapeutics common stock. This award represents her annual equity grant for 2026, as approved by the company’s board of directors earlier in the year.

How were Lori A. Woods’ 2026 Perspective Therapeutics options approved?

The stock option grant to Lori A. Woods was approved by Perspective Therapeutics’ board of directors on January 26, 2026. The formal grant date was set as March 2, 2026, and the award is characterized as her annual equity compensation for 2026.

Is the new CATX stock option grant to Lori A. Woods a purchase or an award?

The CATX transaction is an award, not an open-market purchase. The Form 4 describes it as a grant of stock options, classified as a grant, award, or other acquisition, provided as her annual equity compensation for 2026.